ProBCI
There is a pressing need for predictive biomarkers to personalize bladder cancer treatment. Patients with bladder cancer will be prospectively recruited for the Prospective Bladder Cancer Infrastructure (ProBCI) with longitudinal assessments from primary diagnosis until death. This infrastructure has the following objectives:
- Inform on the epidemiology of bladder cancer in the Netherlands and the treatment evolution landscape;
- Facilitate the selection of eligible patients for specific intervention studies, thereby improving accrual rates;
- Facilitate the identification of historical or concurrent control groups for future single arm intervention studies;
- Validate the efficacy and safety of novel diagnostic and therapeutic approaches in a real-world patient population;
- Evaluate the impact of bladder cancer treatment on patient reported outcomes;
- Provide access to blood and tumor tissue of bladder cancer patients for biomarker discovery and validation studies and organoid culture.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items

Sub-biobank MEMORY
15 September 2020The MEMORY biobank focuses on research into biomarkers for memory impairment and dementia and their validation in clinical cohorts.
read more
RYR1 sub-biobank
15 September 2020The RYR1 biobank is part of a study of the neuromuscular and multisystem features of patients with malignant hyperthermia or rhabdomyolysis related to RYR1 (ryanodine receptor type 1) variants.
read more
New colleague
15 September 2020My name is Robbert Croes and I started mid 2020 as a data-scientist at the Radboud Biobank.
read more
Financial regulation for sub-biobanks
15 September 2020Sub-biobanks are not required to pay up-front for the processing and storage of biomaterials. The effectiveness of this pre-financing agreement however is dependent on adherence to the demands regarding delivery and processing according to the Radboud Biobank standard operating procedures.
read more